Ibrutinib repurposing: From B-cell malignancies to solid tumors

Oncoscience

Volumn 3, Issue 5-6, 2016, Pages 147-148

  Massó Vallés, Daniel ^a   Jauset, Toni ^a   Soucek, Laura ^a,b,c  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

BTK; Drug repurposing; Ibrutinib; Inflammation; Solid tumors

Indexed keywords

EID: 84978292954     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.310     Document Type: Article

References (8)

1. Soucek L, et al. Neoplasia. 2011; 13:1093-1100.
2. Masso-Valles D, et al. Cancer research. 2015; 75:1675-1681.
3. Gunderson AJ, et al. Cancer discovery. 2016; 6:270-285.
4. Stiff A, et al. Cancer research. 2016.
5. Sagiv-Barfi I, et al. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:E966-972.
6. Gao W, et al. Journal of the National Cancer Institute. 2014; 106.
7. Kokabee L, et al. Cancer biology & therapy. 2015; 16:1604-1615.
8. Grassilli E, et al. Oncogene. 2016.